{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:50:59Z","timestamp":1772844659657,"version":"3.50.1"},"reference-count":56,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>ROS1 rearrangements are considered rare in non-small-cell lung cancer (NSCLC). This retrospective real-world study aimed to evaluate first-line treatment with crizotinib, a tyrosine kinase inhibitor (TKI) standard of care vs. new generation ROS1 anti-cancer agents. Forty-nine ROS1-expressing NSCLC patients, diagnosed with advanced metastatic disease, were included. Molecular profiling using either FISH\/CISH or NGS was performed on tissue samples. Twenty-eight patients were treated with crizotinib, while fourteen patients were administered newer drugs (entrectinib, repotrectinib) and seven patients received platinum-doublet chemotherapy in a first-line setting. Overall response rate and disease control rate for the crizotinib and entrectinb\/repotrectinib cohort were 68% and 82% vs. 86% and 93%, respectively. Median progression free survival was 1.6 years (95% CI 1.15\u20132.215) for the crizotinib treatment vs. 2.35 years for the entrectinib\/repotrectinib cohort (95% CI 1.19\u20133.52). Central nervous system progression was noted in 20% and 25% of the crizotinib and entrectinib\/repotrectinib cohorts, respectively. This multi-center study presents real-world treatment patterns of ROS1 NSCLC population, indicating that crizotinib exhibited comparable results to entrectinib\/repotrectinib in a first-line setting, although both response rate and survival was numerically longer with treatment with newer agents.<\/jats:p>","DOI":"10.3390\/curroncol31080326","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T11:54:19Z","timestamp":1722945259000},"page":"4369-4381","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study)"],"prefix":"10.3390","volume":"31","author":[{"given":"Urska","family":"Janzic","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, University Clinic Golnik, 4204 Golnik, Slovenia"},{"name":"Medical Faculty Ljubliana, University of Ljubliana, 1000 Ljubljana, Slovenia"}]},{"given":"Natalie","family":"Maimon Rabinovich","sequence":"additional","affiliation":[{"name":"Lung Oncology Service, Division of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Kfar Saba 4428163, Israel"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7570-4550","authenticated-orcid":false,"given":"Walid","family":"Shalata","sequence":"additional","affiliation":[{"name":"The Legacy Heritage Cancer Center & Dr. Larry Norton Institute, Soroka Medical Center, Ben Gurion University, Beer Sheva 84105, Israel"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4956-9364","authenticated-orcid":false,"given":"Waleed","family":"Kian","sequence":"additional","affiliation":[{"name":"Helmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University, Jerusalem 9436008, Israel"}]},{"given":"Katarzyna","family":"Szymczak","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy and Early Phase Clinical Trials Center, University of Gda\u0144sk, 80-210 Gda\u0144sk, Poland"}]},{"given":"Rafal","family":"Dziadziuszko","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy and Early Phase Clinical Trials Center, University of Gda\u0144sk, 80-210 Gda\u0144sk, Poland"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4815-7512","authenticated-orcid":false,"given":"Marko","family":"Jakopovic","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, 10 000 Zagreb, Croatia"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-7836","authenticated-orcid":false,"given":"Giannis","family":"Mountzios","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, Fourth Oncology Department, Henry Dunant Hospital Center, 115 26 Athens, Greece"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3710-6445","authenticated-orcid":false,"given":"Adam","family":"Pluzanski","sequence":"additional","affiliation":[{"name":"Department of Lung Cancer and Chest Tumors, The Maria Sklodowska-Curie National Research Institute of Oncology, 00-001 Warsaw, Poland"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7267-3584","authenticated-orcid":false,"given":"Antonio","family":"Araujo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, ULS de Santo Ant\u00f3nio, 4099-001 Porto, Portugal"}]},{"given":"Andriani","family":"Charpidou","sequence":"additional","affiliation":[{"name":"Oncology Unit, 3rd Department of Medicine, \u201cSotiria\u201d Hospital for Diseases of the Chest, National and Kapodistrian University of Athens, 106 79 Athens, Greece"}]},{"given":"Sameh","family":"Daher","sequence":"additional","affiliation":[{"name":"Thoracic Cancer Unit, Cancer Division, Rambam Health Care Campus, Haifa 3525408, Israel"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3330-2959","authenticated-orcid":false,"given":"Abed","family":"Agbarya","sequence":"additional","affiliation":[{"name":"Department of Oncology, Bnai-Zion Medical Center, 47 Golomb Avenue, Haifa 31048, Israel"},{"name":"Rappaport Faculty of Medicine, Technion-Israeli Institute of Technology, Haifa 31096, Israel"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2023, January 27). Lung Cancer. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lung-cancer."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Kim, H.H., Lee, J.C., Oh, I.-J., Kim, E.Y., Yoon, S.H., Lee, S.Y., Lee, M.K., Lee, J.E., Park, C.K., and Lee, K.Y. (2024). Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer. Cancers, 16.","DOI":"10.3390\/cancers16030528"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Yang, X., Tang, Z., Li, J., Jiang, J., and Liu, Y. (2023). Progress of non-small cell lung cancer with ROS1 rearrangement. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.1238093"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/curroncol29020057","article-title":"ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date","volume":"29","author":"Gendarme","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Taha, T., Khoury, R., Brenner, R., Nasrallah, H., Shofaniyeh, I., Yousef, S., and Agbarya, A. (2021). Treatment of Rare Mutations in Patients with Lung Cancer. Biomedicines, 9.","DOI":"10.3390\/biomedicines9050534"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"D\u2019angelo, A., Sobhani, N., Chapman, R., Bagby, S., Bortoletti, C., Traversini, M., Ferrari, K., Voltolini, L., Darlow, J., and Roviello, G. (2020). Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies. Cancers, 12.","DOI":"10.3390\/cancers12113293"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"107253","DOI":"10.1016\/j.lungcan.2023.107253","article-title":"Real-world treatment patterns and survival of patients with ROS1 rearranged stage IV non-squamous NSCLC in the Netherlands","volume":"181","author":"Damhuis","year":"2023","journal-title":"Lung Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Stanzione, B., Del Conte, A., Bertoli, E., De Carlo, E., Revelant, A., Spina, M., and Bearz, A. (2023). Therapeutical Options in ROS1-Rearranged Advanced Non Small Cell Lung Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411495"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/OP.20.00819","article-title":"The Road Less Traveled: A Guide to Metastatic ROS1-Rearranged Non-Small-Cell Lung Cancer","volume":"17","author":"Almquist","year":"2021","journal-title":"JCO Oncol. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S779","DOI":"10.21037\/tcr.2018.08.11","article-title":"Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors","volume":"7","author":"Sehgal","year":"2018","journal-title":"Transl. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s00277-020-04357-z","article-title":"Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K","volume":"100","author":"Mian","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): Updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_13","unstructured":"(2024, February 03). Comprehensive Cancer Network (NCCN) Version 1. Non Small Cell Lung Cancer. ROS1 Rearrangement. Available online: https:\/\/mail.google.com\/mail\/u\/1\/#inbox\/FMfcgzGwJcfdHlLfGMxMRHlMsPLVtBkC?projector=1&messagePartId=0.1."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_15","first-page":"100332","article-title":"Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_17","unstructured":"(2024, February 03). FDA Approved Repotrectinib for ROS1-Positive Non-Small Cell Lung Cancer. U.S. Food  & Drug Administration, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-repotrectinib-ros1-positive-non-small-cell-lung-cancer."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41571-024-00864-4","article-title":"Repotrectinib effective in ROS1-fusion-positive NSCLC","volume":"21","author":"Sidaway","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Janzic, U., Shalata, W., Szymczak, K., Dziadziuszko, R., Jakopovic, M., Mountzios, G., P\u0142u\u017ca\u0144ski, A., Araujo, A., Charpidou, A., and Agbarya, A. (2023). Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241612840"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/1759-7714.12917","article-title":"PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1","volume":"10","author":"Lee","year":"2019","journal-title":"Thorac. Cancer"},{"key":"ref_21","unstructured":"(2024, February 22). Crizotinib Dosage. Available online: https:\/\/www.ema.europa.eu\/en\/search?search_api_fulltest=crizotinib."},{"key":"ref_22","unstructured":"(2024, February 22). Entrectinib Dosage. Available online: https:\/\/www.ema.europa.eu\/en\/search?search_api_fulltest=entrectinib."},{"key":"ref_23","unstructured":"(2024, February 22). Repotrectinib Dosage. Available online: https:\/\/www.ema.europa.eu\/en\/search?search_api_fulltest=repotrectinib."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.21037\/atm.2018.04.04","article-title":"Novel chemotherapy regimens for advanced lung cancer: Have we reached a plateau?","volume":"6","author":"Baxevanos","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_26","unstructured":"Rare Mutations and Fusions in NSCLC (2024, July 18). Navigating Rare Mutations & Fusions. Available online: https:\/\/rare-mutations.lungevity.org\/rare-mutations\/about-rare-mutations-and-fusions-nsclc#:~:text=Approximately%203%25%2D4%25%20of,a%20minority%20are%20never%2Dsmokers."},{"key":"ref_27","unstructured":"EGFR and Lung Cancer (2024, July 18). American Lung Association. Available online: http:\/\/www.lung.org\/lung-health-diseases-lookup\/lung-cancer\/symptoms-diagnosis\/biomarker-testing\/egfr#:~:text=Who%20is%20likely%20to%20have,minimal%20to%20no%20smoking%20history."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2013.54.5921","article-title":"Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project","volume":"32","author":"Blackhall","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jtho.2023.12.009","article-title":"CD74\/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutation","volume":"19","author":"Li","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: Integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1080\/14656566.2020.1798932","article-title":"Evaluating entrectinib as a treatment option for non-small cell lung cancer","volume":"21","author":"Lee","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40265-021-01503-3","article-title":"Entrectinib: A Review in NTRK+ Solid Tumours and ROS1 + NSCLC","volume":"81","author":"Frampton","year":"2021","journal-title":"Drugs"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in Advanced ROS1-Positive Non-Small-Cell Lung Cancer: A Multicentre, Open-Label, Single-Arm, Phase 1\u20132 Trial","volume":"20","author":"Shaw","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Jiang, Q., Li, M., Li, H., and Chen, L. (2022). Entrectinib, a new multi-target inhibitor for cancer therapy. Biomed Pharmacother., 150.","DOI":"10.1016\/j.biopha.2022.112974"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","article-title":"ROS1-dependent cancers-biology, diagnostics and therapeutics","volume":"18","author":"Drilon","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/acs.jmedchem.6b00064","article-title":"Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor","volume":"59","author":"Menichincheri","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/1535-7163.MCT-15-0758","article-title":"Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications","volume":"15","author":"Ardini","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jtho.2017.08.002","article-title":"Recent Advances in Targeting ROS1 in Lung Cancer","volume":"12","author":"Lin","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"10343","DOI":"10.2147\/OTT.S230309","article-title":"Recent Progress in Rare Oncogenic Drivers and Targeted Therapy for Non-Small Cell Lung Cancer","volume":"12","author":"Guo","year":"2019","journal-title":"Onco. Targets Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6628","DOI":"10.3390\/curroncol29090520","article-title":"Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy","volume":"29","author":"Falk","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0959-8049(16)32675-2","article-title":"TPX-0005, a novel ALK\/ROS1\/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants","volume":"69","author":"Cui","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40265-023-01990-6","article-title":"Repotrectinib: First Approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11523-021-00860-z","article-title":"Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study","volume":"17","author":"Waterhouse","year":"2022","journal-title":"Target Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s12094-020-02376-w","article-title":"Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer","volume":"22","author":"Dudnik","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00280-019-03902-6","article-title":"Resistance Mechanisms and Potent-Targeted Therapies of ros1-Positive Lung Cancer","volume":"1284","author":"Roys","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1215530","article-title":"Acquired Resistance to Crizotinib from a Mutation in CD74\u2013ROS1","volume":"368","author":"Awad","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40265-019-01164-3","article-title":"Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors","volume":"79","author":"Morris","year":"2019","journal-title":"Drugs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1073\/pnas.1420785112","article-title":"PF-06463922 is a Potent and Selective Next-Generation ROS1\/ALK Inhibitor Capable of Blocking Crizotinib-Resistant ROS1 Mutations","volume":"112","author":"Zou","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","unstructured":"(2024, February 22). Pfizer\u2019s Next-Generation ALK\/ROS1 Inhibitor, Lorlatinib, Granted Breakthrough Therapy Designation from FDA for ALK-Positive Metastatic Non-Small Cell Lung Cancer, Pfizer. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_s_next_generation_alk_ros1_inhibitor_lorlatinib_granted_breakthrough_therapy_designation_from_fda_for_alk_positive_metastatic_non_small_cell_lung_cancer."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S989","DOI":"10.1016\/j.annonc.2021.08.1865","article-title":"ROS1 resistance mutations and co-occurring genetic alterations to the ROS1 protein-tyrosine kinase inhibitors (crizotinib) in lung cancer","volume":"32","author":"Weng","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_51","first-page":"16","article-title":"ROS-1 NSCLC therapy resistance mechanism","volume":"4","author":"Calles","year":"2021","journal-title":"PCM"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"9584","DOI":"10.1038\/s41598-023-36623-1","article-title":"Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting","volume":"13","author":"Belaroussi","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1002\/cam4.2984","article-title":"Crizotinib vs. platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants","volume":"9","author":"Xu","year":"2019","journal-title":"Cancer Med."},{"key":"ref_54","unstructured":"(2024, February 22). A Study of Repotrectinib Versus Crizotinib with Locally Advanced or Metastatic TKI-Na\u00efve ROS1 Positive Non-Small Cell Lung Cancer TRIDENT-3, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06140836."},{"key":"ref_55","unstructured":"(2024, February 22). Lorlatinib after Failure of First-Line TKI in Patients with Advanced ROS1-Positive NSCLC (ALBATROS), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04621188."},{"key":"ref_56","unstructured":"(2024, February 22). A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants with Advanced or Metastatic ROS1 NSCLC with and without CNS Metastases [NCT 04603807], Available online: https:\/\/clinicaltrials.gov\/study\/NCT04603807."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/8\/326\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:26:19Z","timestamp":1760109979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/8\/326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":56,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["curroncol31080326"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31080326","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]}}}